DIABETES THERAPY TO IMPROVE BMI AND PULMONARY FUNCTION IN CYSTIC FIBROSIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。(1)与对照组相比，接受胰岛素或瑞格列奈治疗的参与者体重指数会增加。(2)胰岛素在提高BMI方面比瑞格列奈更有效。(3)体重指数的增加主要是由于肌肉量的增加。(4)在饮食常量营养素或热量组成没有显著变化的情况下，可以实现BMI的增加。(5)胰岛素或瑞格列奈治疗可以预防肺功能下降，与对照组和前一年测量的自己的基线相比。这将与NIH临床评分的改善有关，并将与体重增加和大腿肌肉体积增加直接相关。(6)接受胰岛素或瑞格列奈治疗的参与者会提高握力，这将与体重增加和大腿肌肉体积增加直接相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (1) Participants receiving either insulin or repaglinide will increase their BMI compared to control participants. (2) Insulin will be more effective than repaglinide at increasing BMI. (3) The increase in BMI will be primarily due to increased muscle mass. (4) The increase in BMI will be accomplished without significant changes in dietary macronutrient or calorie composition. (5) Insulin or repaglinide therapy will prevent pulmonary function decline compared to both control subjects and to their own baseline as measured the previous year. This will be associated with improvement in NIH clinical score and will be directly related to weight gain and increase in thigh muscle volume. (6) Participants receiving insulin or repaglinide will improve hand grip strength, and this will be directly related to weight gain and increase in thigh muscle volume.